MétaCan
Menu
Back to cohort
Record W4415388021 · doi:10.1002/mds.70090

Feasibility of Simon Two‐Stage Futility Trials in People with Early, Symptomatically Treated Parkinson's Disease

2025· article· en· W4415388021 on OpenAlexafffund
Marcus Koch, Lorraine V. Kalia, Justyna R. Sarna, Camila Aquino, Daryl Wile, Tiago Mestre, Michael G. Schlossmacher, Miguel D’haeseleer, Jop Mostert, Eva Strijbis, Bernard M.J. Uitdehaag, Tarrant McPherson, Gary Cutter

Bibliographic record

VenueMovement Disorders · 2025
Typearticle
Languageen
FieldMedicine
TopicParkinson's Disease Mechanisms and Treatments
Canadian institutionsUniversity of British ColumbiaUniversity of OttawaOttawa HospitalToronto Western HospitalUniversity of TorontoUniversity of Calgary
FundersCilagSanofi GenzymeGenentechMitsubishi Tanabe Pharma CorporationAlexion PharmaceuticalsUniversity of TorontoAmgenHorizon PharmaceuticalsParkinson CanadaSanofiGW PharmaceuticalsRegeneron PharmaceuticalsFondation Brain CanadaUniversity of OttawaKrembil FoundationUniversity of PennsylvaniaCanadian Institutes of Health ResearchProthenaNeuraxpharmTeva Pharmaceutical IndustriesAveXisInternational Parkinson and Movement Disorder SocietyBiogenPTC TherapeuticsCelgeneCHDI FoundationCSL BehringBristol-Myers SquibbMichael J. Fox Foundation for Parkinson's Research
KeywordsClinical trialMovement disordersDiseaseMEDLINEOutcome (game theory)Drug trial

Abstract

fetched live from OpenAlex

BACKGROUND: Disease-modifying treatments are a critical unmet need in Parkinson's disease (PD). Phase 2 futility trials using the Simon two-stage design offer an efficient strategy to evaluate candidate treatments in an early PD population. OBJECTIVE: The aim was to assess the feasibility of Simon two-stage futility trials in early, levodopa-treated PD subjects using historical patient-level clinical trial datasets. METHODS: We analyzed patient-level data from two completed trials, that is, STEADY-PD 3 (n = 336, untreated at baseline) and NET-PD LS1 (n = 1741, treated at baseline). We defined disability progression as a ≥5-point worsening on the motor (Part III) subscore of the Unified Parkinson's Disease Rating Scale at 12 and 24 months. We tested multiple scenarios, including the reanalysis of STEADY-PD 3 participant data after starting dopaminergic treatment. We assessed predictors of progression using logistic regression analysis and calculated sample size estimates. RESULTS: Both trials showed similar progression rates at 12 months (~26%) and 24 months (~35%). In NET-PD LS1, older age and lower baseline motor scores were associated with worsening; no predictors were significant in STEADY-PD 3. We estimate that in futility trials that use OFF-state scores to assess motor performance, 39 early PD participants are required to detect significant disability worsening over an observation period of 12 months. CONCLUSIONS: Phase 2 futility trials using the Simon two-stage methodology are feasible in early PD, including in treated and untreated patients. OFF-state scores are preferable to ON-state scores as the primary outcome measure. Futility trials offer a smaller-scale, faster, and cost-effective approach to assessing new candidate treatments in PD. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.171
metaresearch head score (Gemma)0.179
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.171
Threshold uncertainty score0.903

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1710.179
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.004
Bibliometrics0.0010.001
Science and technology studies0.0010.002
Scholarly communication0.0020.003
Open science0.0010.002
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.312
Teacher spread0.290 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueMovement DisordersSame topicParkinson's Disease Mechanisms and TreatmentsFrench-language works237,207